Epidemiology and risk factors.

摘要: HBC is common, accounting for approximately 9% of the total breast cancer burden. Given 142,000 cases expected to occur in 1989, this would represent 12,780 patients. Soberingly, each patient represents a family with variable number inordinately high risk HBC's natural history distinctive and enables identification at patients who can benefit from highly targeted surveillance/management strategies. High priority must be given development biomarkers that will one day found have acceptable sensitivity specificity genotype status. Thus, we then able tell which first-degree relatives affected members inherited deleterious gene. This result significant saving time money otherwise expended through intensive surveillance We need cost-benefit research induce third party carriers defray expenses surveillance. Finally, attention biomolecular markers cancer-prone genotype. Eventual cloning gene(s) could lead knowledge about its chemical physiologic products, thereby enabling anticancer pharmacologic research. The reward improved control even prevention cancer, possibly associated cancers heterogenous forms disease.